Sydney, Australia: Proteome Systems (ASX:PXL) today announced a collaboration with Prince Henry's Institute Medical Research (PHIMR) to combine their IP and expertise in ovarian cancer for the discovery and development of novel diagnostic markers.
- If ovarian cancer is detected early there is a very good prognosis for full recovery. Currently, there is no test for early detection of ovarian cancer.
- PXL has patented several protein and carbohydrate candidate markers for the development of an ovarian cancer diagnostic test.
- Melbourne-based PHIMR has previously developed a test to detect ovarian cancer in post-menopausal woman, a significant sector of the target population.
Of all the gynaecologic cancers, ovarian malignancies represent the greatest clinical challenge. Around 1 in 56 women will develop ovarian cancer during their lifetime. Due to the absence of clear symptoms, ovarian cancer is usually detected when it has already spread beyond the ovary. At this relatively late stage the 5 year survival rate has decreased to ~30% while if the cancer is detected when confined to the ovary, the corresponding 5-year survival rate is >85%. This has led to the need to develop markers that can detect ovarian cancer at this early stage.
Proteome Systems has discovered and patented novel markers for epithelial ovarian cancer using its proprietary proteomic and glycoproteomic technology platforms. The company is actively seeking partnerships with academic and clinical groups with expertise in ovarian cancer to further expand its portfolio of ovarian cancer markers and clinically evaluate these for the development of a diagnostic test.
Associate Professor David Robertson leads the team at PHIMR that has previously developed a test to diagnose ovarian cancer (Robertson et al., 2002; Robertson and Oehler, 2005). The test is useful for initial diagnosis and monitoring recurrence of the disease in post-menopausal women, but iPage: 1 2 Related medicine news :1
Contact: Jenny Harry
. Proteome Systems Ltd and US-based Egenix Inc to develop semen-based test for prostate cancer2
. Proteome Systems raises $10m through a private placement to institutional and professional investors3
. Ossur v. Bledsoe Brace Systems4
. Pot bellies linked to early signs of cardiovascular disease5
. Heading to Siberia: UH signs agreement with Russian Academy of Sciences6
. Most young women dont recognize heart attack warning signs7
. Mice with a migraine show signs of brain damage8
. New cigarette designs dont offer lower predicted cancer risks9
. USP signs Memorandum of Understanding with the Pharmaceutical Export Promotion Council10
. Noise-immune stethoscope helps medics hear vital signs in loud environments11
. Before dementias first signs appear, weight-loss rate doubles in elderly